

**Form 51-102F3  
MATERIAL CHANGE REPORT**

**Item 1: Name and Address of Company**

BioMark Diagnostics Inc. (“the **Issuer**”)  
165 – 10551 Shellbridge Way  
Richmond, BC V6X 2W8

**Item 2: Date of Material Change**

November 3, 2014

**Item 3: News Release**

A news release was issued and disseminated on November 3, 2014 and filed on SEDAR ([www.sedar.com](http://www.sedar.com)). A copy of the news release is attached as Schedule “A” hereto.

**Item 4: Summary of Material Change**

The Issuer announced that its Common Shares have commenced trading on the Canadian Securities Exchange under the symbol “BUX” on November 3, 2014.

**Item 5: Full Description of Material Change**

Please see the attached Schedule “A”.

**Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable

**Item 7: Omitted Information**

None

**Item 8: Executive Officer**

Rashid Ahmed Bux, President & CEO  
Telephone: 604.282.6567  
Email: [info@biomarkdiagnostics.com](mailto:info@biomarkdiagnostics.com)

**Item 9: Date of Report**

November 3, 2014

## Schedule "A"



165 – 10551 Shellbridge Way  
Richmond, BC V6X 2W8

### **BIOMARK DIAGNOSTICS INC. APPROVED FOR LISTING AND COMMENCES TRADING ON THE CSE**

**Vancouver, B.C. – (November 3, 2014) BioMark Diagnostics Inc. ("BioMark")** (CSE:BUX) is pleased to announce that it has received approval to list its Common Shares for trading on the Canadian Securities Exchange ("CSE"), and that its Common Shares have commenced trading as of the opening of market, today, November 3, 2014, under the trading symbol "BUX".

#### **About BioMark**

BioMark is a Canadian based company that is in the process of developing an advanced stage cancer diagnostic business. BioMark's cancer diagnostics technology has developed to date into a metabolomics-based diagnostic assay that allows for early cancer detection. BioMark is currently focused on bringing its cancer diagnostic kits and detection system up to commercialization standards and hopes to commence distribution once clinical trials are complete and regulatory acceptance is obtained.

Further information about BioMark is available under its profile on the SEDAR website [www.sedar.com](http://www.sedar.com) and on the CSE website [www.thecse.ca](http://www.thecse.ca).

#### **For further information on BioMark, please contact:**

Rashid Ahmed Bux  
President & Chief Executive Officer  
BioMark Diagnostics Inc.  
Telephone 604.282.6567  
Email: [info@biomarkdiagnostics.com](mailto:info@biomarkdiagnostics.com)

#### **Forward-Looking Information:**

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-

looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.